Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study
Tofacitinib showed promising clinical efficacy in patients experiencing irAEs, particularly in patients who failed to respond to steroids or experienced relapse during steroid tapering. Moreover, and most importantly, tofacitinib exhibited a favorable safety profile in cancer patients developing irAEs in terms of both toxicity and anti-tumor activity. Future prospective studies are warranted.
Authors
- Yiyi Yu (ORCID: https://orcid.org/0000-0002-8444-0235)
- Jiahua Zhou (ORCID: https://orcid.org/0000-0003-0551-5604)
- Xiao‐Dong Jiao (ORCID: https://orcid.org/0000-0002-9663-8548)
- Zhiguo Zou (ORCID: https://orcid.org/0000-0001-9028-9239)
- Ning‐Ping Zhang (ORCID: https://orcid.org/0000-0003-1262-4331)
- Qing Liu (ORCID: https://orcid.org/0000-0002-2199-2999)
- Haojie Zhou (ORCID: https://orcid.org/0000-0002-2536-2222)
- Tianshu Liu (ORCID: https://orcid.org/0000-0002-8604-6311)
- Lin Zhao (ORCID: https://orcid.org/0000-0001-8793-5893)
- Jinyi Lin
- Mengling Liu
- Xin Zhou (ORCID: https://orcid.org/0000-0003-3067-5677)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Renji Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai Changzheng Hospital (CN)
- Shanghai Xuhui Central Hospital (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shanghai Construction Group (China) (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1186/s12967-024-05617-6
- Citations
- 18
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.09
Funders
- Fudan University
- Chinese Society of Clinical Oncology
- Zhongshan Hospital
- Shanghai Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines